Clinical Trials Logo

Clinical Trial Summary

Evaluation of the efferocytosis capacities of blood Monocyte Derived Macrophages (MDM) from patients with a history of asbestosis or silica exposure and comparison of these capacities with those of MDM from healthy donors.


Clinical Trial Description

Patients with a proven history or current exposure will have 4 EDTA tubes drawn, approximately 24mL of fresh whole blood for efferocytosis assessment and : - 2 x 6mL serum tubes for the assessment of Antinuclear Antibody (ANA) positivity, serum high-mobility group box 1 (HMGB1) and osteopontin for patients exposed to asbestos - 1 x 6mL serum tube for serum HMGB1 and osteopontin for patients exposed to silica ;


Study Design


Related Conditions & MeSH terms

  • Asbestosis
  • Autoimmune Diseases
  • History of Exposure to Silica or Asbestosis
  • Positive Testing for ANA as a Marker of Systemic Autoimmune Diseases

NCT number NCT04473742
Study type Interventional
Source Rennes University Hospital
Contact
Status Completed
Phase N/A
Start date March 31, 2021
Completion date December 15, 2021